BioWorld

Oct. 24, 2005

Syntonix, Boehringer Enter $63M Inhaled Peptide Deal

For the second time this year, an international drug company is showing a strong interest in Syntonix Pharmaceuticals Inc.'s Synfusion and Transceptor technologies - this time to the tune of up to $63 million. (BioWorld Today) Read More

Maxygen Awarded $14.4M Of Fed's Money For HIV Vaccine

Blocking Immune Signals To Brain Helps Sickness Healing

Biodefense Budget Dissected; Some Feel More Money Needed

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for March 25, 2026.

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026